Clinical Trial Update: A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing ixekizumab to guselkumab in moderate-to-severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)
• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2020-07-28